MA grocery card use was associated with modest increases in wellness, primary care, and specialist visits among dual-eligible ...

Doxy-PEP reshapes STI prevention, while congenital syphilis surges; experts urge scaling HIV and STI care infrastructure to ...

Victor Appay, PhD, explains how long-term ART slows immune aging, boosting HIV viral suppression and paving the way for ...

Cost concerns among GLP-1 users extend beyond individual financial strain to perceptions of broader health care system sustainability. More than 70% of respondents supported minimum coverage ...

The largest nursing strike came to an end on February 21, 2026, after 41 days. The 3 health systems being protested, Mount Sinai, NewYork-Presbyterian, and Montefiore, addressed nurses’ demands and ...

Tina Bhatnagar, DO, speaks to the importance of diversity in clinical trials and the need to remove barriers, enroll underrepresented backgrounds, and reflect real-world health conditions. The push ...

Executive actions in 2025 produced a 90-day freeze and stop orders; waivers incompletely restored services, with notable gaps in PrEP access for nonpregnant, nonbreastfeeding individuals. New research ...

Mark Meiselbach, PhD, at Johns Hopkins Bloomberg School of Public Health, explains Medicare Advantage market corrections, Star Rating System pressures, and rural plan exits.

GLP-1 receptor agonists improve glycemic control and weight while reducing cardiovascular events, with tolerability limited by gastrointestinal adverse effects requiring gradual dose escalation.

The increase in CRC-related mortality in younger adults is driven by screening delays and advanced-stage diagnoses, according to Jordan Karlitz, MD.

LIBERTY-AFRS-AIMS met its primary endpoint with a 50% reduction in CT sinus opacification at week 52 versus 10% with placebo (P<.0001).

Today, the FDA issued draft guidance outlining a new regulatory pathway intended to help sponsors gain approval for highly ...